Table 3.
Side effects/Adverse events occurring in any group and ranked by overall incidence
| Side effects/Adverse events | Topiramate N = 344 |
Placebo N = 139 |
|---|---|---|
| Paresthesia | 71(20.64)a | 4(2.88) |
| Upper respiratory tract infection | 54(15.7) | 16(9.35) |
| Fatigue | 48(13.95) | 11(7.91) |
| Weight decrease | 39(11.34) | 5(3.59) |
| Abdominal pain | 22(6.40) | 12(8.63) |
| Anorexia | 26(7.56) | 7(5.03) |
| Dry mouth | 26(7.56) | 4(2.88) |
| Pharyngitis | 16(4.65) | 13(9.35) |
| Memory impairment | 24(6.98) | 3(2.16) |
| Injury | 16(4.65) | 11(7.91) |
| Cognitive disorder | 23(6.69) | 4(2.88) |
| Aphasia | 23(6.69) | 3(2.16) |
| Sinusitis | 14(4.07) | 7(5.03) |
| Nausea | 11(3.20) | 5(3.59) |
| Altered mood | 14(4.07) | 2(1.44) |
| Dizziness | 14(4.07) | 1(0.72) |
| Somnolence | 11(3.20) | 3(2.16) |
| Gastroenteritis | 10(2.91) | 3(2.16) |
| Fever | 10(2.91) | 2(1.44) |
| Influenza-like symptoms | 8(2.33) | 2(1.44) |
| Sedation | 4(1.16) | 2(1.44) |
| Rhintis | 5(1.45) | 1(0.72) |
| Insomnia | 4(1.16) | 1(0.72) |
| Viral infection | 4(1.16) | 1(0.72) |
| Back pain | 2(0.58) | 3(2.16) |
| Conjunctivitis | 4(1.16) | 1(0.72) |
| Lack of concentration in school# | 4(1.16) | 0(0) |
| Coughing# | 4(1.16) | 0(0) |
| Taste perversion# | 4(1.16) | 0(0) |
| Abnorma vision | 3(0.87) | 1(0.72) |
| Eye pain | 2(0.58) | 2(1.44) |
| Vomiting | 2(0.58) | 1(0.72) |
| Nervousness# | 3(0.87) | 0(0) |
| Asthma# | 2(0.58) | 0(0) |
| Pneumonia# | 2(0.58) | 0(0) |
| Allergy# | 2(0.58) | 0(0) |
| Respiratory:bronchospasm | 1(0.29) | 1(0.72) |
| Suicide attempt# | 1(0.29) | 0(0) |
| Intussusception# | 1(0.29) | 0(0) |
| Traumatic liver injury# | 1(0.29) | 0(0) |
An individual subject might have experienced more than one side effect or adverse event
aValues expressed as N (%)
#Reported only in the topiramate treatment group